Clicky

Regeneus Ltd  (RGS)

Description: Regeneus Ltd is a clinical-stage regenerative medicine company. The Company is engaged in developing cell-based therapies for human and animal health markets, with a focus on osteoarthritis and musculoskeletal disorders, as well as oncology and dermatology diseases. The Company's portfolio of therapeutic products is being developed using stem cell and immune oncology technology platforms. The Company's technology platform includes approximately three platforms across both human and animal health businesses, including Human and animal adipose-derived mesenchymal stem cells (MSCs) for the treatment of musculoskeletal diseases; Human and animal immunotherapy personalized cancer vaccine for the treatment of various cancers, and Stem cell secretions cell free supernatant (CFS) technology harnessing the therapeutic potential of mesenchymal stem cells for skincare treatments. The Company's products include Kvax, CryoShot, Progenza, Human Cancer Vaccine and Secretions Cream.


Keywords: Medicine Biotechnology Cancer Life Sciences Biology Disease Oncology Immunotherapy Stem Cell Disorders Cell Biology Arthritis Regenerative Medicine Therapeutic Products Dermatology Osteoarthritis Stem Cell Therapy Induced Stem Cells Mesenchymal Stem Cell Treatment Of Various Cancers Regenerative Musculoskeletal Disorders Dermatology Diseases Musculoskeletal Diseases

Home Page: regeneus.com.au

RGS Technical Analysis

Allianz Funds
,

Phone: 1300 995 098


Officers

Name Title
Mr. Karolis Rosickas Chief Exec. Officer
Prof. Graham Vesey Ph.D. Chief Scientific Officer & Exec. Director
Dr. Charlotte Morgan Ph.D. Head of R&D
Ling Leung Hang Company Sec.

Exchange: AU

Country: AU

Currency: Australian Dollar (A$)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 13.6854
Price-to-Sales TTM: 28.0168
IPO Date:
Fiscal Year End: June
Full Time Employees: 0
Back to stocks